Streptococcal C5a peptidase vaccine
AssigneeRegents of the University of Minnesota
InventorsPaul Patrick Cleary, Deborah K. Stafslien
Life of this patent
Estimating the term…
Abstract
Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
Claims17
An isolated and purified enzymatically inactive peptide of peptide of Streptococcal C5a peptidase (SCP), wherein the peptide comprises the catalytic domain of the SCP, which elicits antibodies that neutralize the peptidase activity of wild-type SCP.
Dependencies are inferred from the claim text.